MNMasatoshi Nishimoto

Masatoshi Nishimoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Masatoshi Nishimoto has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Body Shape Index and Risk of Kidney Function Decline in Older Adults with CKD

    by Takaaki Kosugi, Masahiro Eriguchi, Hisako Yoshida, Hiroyuki Tamaki, Takayuki Uemura, Hikari Tasaki, Riri Furuyama, Masatoshi Nishimoto, Katsuhiko Morimoto, Masaru Matsui, et al.

    Background: A Body Shape Index has recently emerged as a useful obesity marker for predicting adverse events. Although its usefulness has been reported even in older adults, who tend to exhibit the obesity paradox, little evidence is available regarding the association between A Body Shape Index and kidney outcomes. This study aimed to investigate the associations between A Body Shape Index or body mass index (BMI) and kidney outcomes in older adults with CKD. Methods: This nationwide longitudinal observational study included individuals aged 65–74 years with CKD who underwent annual health checkups between 2008 and 2014. Exposures of interest were A Body Shape Index and BMI, and the primary outcome was a 40% decline in estimated glomerular filtration rate (eGFR). The associations between quartiles (Q1–Q4) of A Body Shape Index and BMI and a 40% decline in eGFR were assessed using Cox regression analysis for each sex. Restricted cubic spline analysis was performed to investigate nonlinear associations. The eGFR trajectory across A Body Shape Index categories was evaluated using a mixed-effects model. Results: Among 31,292 men and 23,167 women with CKD, 544 men and 315 women experienced a 40% decline in eGFR during a median follow-up of 26.4 months. Compared to Q1 of A Body Shape Index, Q3 and Q4 were associated with the kidney outcome in men, with adjusted hazard ratios and 95% confidence intervals of 1.32 (1.01–1.71) and 1.72 (1.34–2.21), respectively. The rate of eGFR decline over time was also greater in these categories in men. In contrast, the association between high values of A Body Shape Index and kidney outcomes did not reach statistical significance in women. High BMI was not associated with kidney outcomes in either sex. Conclusions: Higher values of A Body Shape Index were associated with CKD progression in older men in Japan, whereas this association was less evident in women.

  • Fibroblast Growth Factor 23, Urinary Phosphate, and Risk of Progression of CKD

    by Takaaki Kosugi, Masahiro Eriguchi, Hiroyuki Tamaki, Riri Furuyama, Mari Nakanishi, Takayuki Uemura, Hikari Tasaki, Masatoshi Nishimoto, Kaori Tanabe, Keisuke Okamoto, et al.

    Key Points: High intact fibroblast growth hormone 23 levels, measured by automated chemiluminescent enzyme immunoassay, were associated with composite kidney outcomes in non–dialysis-dependent CKD. The association between intact fibroblast growth hormone 23 levels and outcomes was more pronounced in patients with low 24-hour urinary phosphate excretion. Fibroblast growth hormone 23 with 24-hour urinary phosphate excretion may assist in predicting the progression of CKD. Background: Association between fibroblast growth hormone 23 (FGF23) levels and kidney outcomes and the effect of urinary phosphate excretion (UPE) on this association remain uncertain. This study aimed to investigate the association between FGF23 levels and kidney outcomes on the basis of UPE levels. Methods: This observational study included 946 patients with non–dialysis-dependent CKD at a tertiary medical center in Japan. Intact FGF23 (iFGF23) levels were measured using an automated chemiluminescent enzyme immunoassay. The association between iFGF23 levels and composite kidney failure with replacement therapy and a 40% decline in eGFR was investigated using Cox regression analysis. A nonlinear relationship was investigated using restricted cubic spline analysis. Subgroup analyses on the basis of 24-hour UPE and fractional excretion of phosphate were also performed. Results: The median eGFR level was 46 ml/min per 1.73 m 2 . During a median follow-up period of 27.2 months, 181 patients experienced composite kidney outcomes. Multivariable Cox regression analysis showed that the risk of composite kidney outcomes was higher in the highest FGF23 category of quartile 4 compared with that in a reference category of quartile 1, with a hazard ratio of 2.12 (95% confidence interval: 1.05 to 4.28). Restricted cubic spline analysis yielded consistent results. The association between high FGF23 levels and composite kidney outcomes was more pronounced in patients with low 24-hour UPE levels. However, fractional excretion of phosphate did not modify this association. Conclusions: High iFGF23 levels are associated with composite kidney outcomes in patients with non–dialysis-dependent CKD. This association was more pronounced in those with low 24-hour UPE levels.


  • Open Access

    Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Lower eGFR Decline in Nondiabetic CKD Patients without Proteinuria

    by Masaru Matsui, Takaaki Kosugi, Kosuke Tansho, Shunsuke Kitamura, Masatoshi Nishimoto, Keisuke Okamoto, Masahiro Eriguchi, Ken-Ichi Samejima, Kazuhiko Tsuruya

    Key Points: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) significantly slowed chronic decline in eGFR in nondiabetic CKD patients without proteinuria. Propensity score–matched analysis confirmed that SGLT2i users had a significantly slower postinitial dip eGFR slope than nonusers. Subgroup analyses consistently supported the renoprotective effect of SGLT2is in this population. Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have shown promise as renoprotective agents, building on the success of renin-angiotensin system blockers. Although SGLT2is have been shown to slow renal deterioration in diabetic and nondiabetic CKD with proteinuria, it is unclear whether similar effects occur in nondiabetic, nonproteinuric CKD. Methods: This study used propensity score analysis to evaluate the effects of SGLT2is on changes in annual eGFR in nondiabetic CKD patients with trivial proteinuria (urinary protein–creatinine ratio 2 , and median urinary protein–creatinine ratio of 0.15 (0.09–0.29) g/gCr. Results: Adjusted linear mixed-effects models showed that while the eGFR decline over a 3-year period (total) was similar between the two groups, there was a significantly smaller decline between 3 months after baseline and 2-year follow-up (chronic) in SGLT2i users compared with nonusers, with a difference of 1.23 (95% confidence interval, 0.43 to 2.02; P = 0.002) ml/min per 1.73 m 2 per year. After propensity score matching, SGLT2i users exhibited significantly slower chronic decline than nonusers, with a difference of 1.50 (95% confidence interval, 0.63 to 2.36; P < 0.001) ml/min per 1.73 m 2 per year. Subgroup analyses confirmed these findings. Conclusions: This study suggests that SGLT2is may slow eGFR decline in non-diabetic CKD patients with trivial proteinuria, supporting the potential use of SGLT2is as renoprotective agents in this population.


  • Open Access

    Efficacy and Safety of Phosphate-Lowering Agents for Adult Patients with CKD Requiring Dialysis

    by Masatoshi Nishimoto, Takeshi Hasegawa, Miho Murashima, Hisashi Noma, Hiroki Nishiwaki, Shunsuke Yamada, Aya Mizukami, Hirotaka Saito, Hiroshi Kimura, Masatomo Taniguchi, et al.

    Key Points: Sevelamer was associated with lower all-cause mortality compared with calcium-based agents. Sucroferric oxyhydroxide and tenapanor were estimated to rank high in lowering all-cause mortality compared with other phosphate-lowering agents. Sucroferric oxyhydroxide and lanthanum were associated with slower progression of coronary artery calcium score compared with calcium-based agents. Background: It is necessary to update the evidence of each phosphate-lowering agent on dialysis patients. Methods: From the CENTRAL, MEDLINE, Embase, and ClinicalTrial.gov databases, randomized controlled trials using oral phosphate-lowering agents on adult patients requiring maintenance dialysis were extracted. The treatment period was required for 8 or more weeks, and the risk of bias was assessed according to the Cochrane Collaboration method. The outcomes were all-cause mortality, cardiovascular mortality, gastrointestinal events, fracture, coronary artery calcium score (CACS), serum calcium, phosphate, intact parathyroid hormone, and bicarbonate levels. A network meta-analyses using multivariate random-effects models were performed for assessing the comparative effectiveness. The ranking of the phosphate-lowering agents was assessed using a surface under the cumulative ranking curve. Results: A total of 70 randomized controlled trials involving 15,551 participants were included. Eleven phosphate-lowering agents including calcium-based agents, sevelamer, bixalomer, lanthanum, sucroferric oxyhydroxide, ferric citrate, tenapanor, magnesium, nicotinamide, aluminum, and sucralfate were assessed. Sevelamer was significantly associated with lower all-cause mortality compared with calcium-based agents (risk ratio [95% confidence interval]: 0.59 [0.37 to 0.94]), and sucroferric oxyhydroxide and tenapanor were estimated to rank high in lowering all-cause mortality on the basis of the surface under the cumulative ranking curve. The risk of gastrointestinal events was the highest with nicotinamide, followed by sucroferric oxyhydroxide. Compared with calcium-based agents, CACS was significantly lower among those on lanthanum and sucroferric oxyhydroxide (standardized mean difference [95% confidence interval]: −0.26 [−0.52 to −0.01] and −0.50 [−0.95 to−0.06], respectively). Serum calcium levels were higher, and serum intact parathyroid hormone levels were lower in patients treated with calcium-based agents. Except for sevelamer, serum bicarbonate levels for all other agents were higher compared with placebo. Conclusions: Compared with calcium-based agents, sevelamer was associated with lower all-cause mortality, and sucroferric oxyhydroxide and lanthanum were associated with slower progression of CACS. Potential benefits and harms should be considered when selecting phosphate-lowering agents (International prospective register of systematic reviews: CRD42022328388).